RA Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-2,531,445
Closed -$84.2M 75
2020
Q2
$84.2M Hold
2,531,445
1.64% 22
2020
Q1
$68.9M Buy
2,531,445
+1,085,644
+75% +$30.2M 2.18% 18
2019
Q4
$28.5M Buy
+1,445,801
New +$23.1M 0.87% 25
2019
Q2
Sell
-2,563,657
Closed -$37.3M 33
2019
Q1
$37.3M Buy
2,563,657
+5,300
+0.2% +$67.7K 1.61% 18
2018
Q4
$28.2M Buy
2,558,357
+1,000,000
+64% +$13.9M 1.64% 18
2018
Q3
$41M Sell
1,558,357
-2,144,176
-58% -$58M 2.19% 17
2018
Q2
$75.7M Buy
+3,702,533
New +$79.5M 4.92% 5

Other funds holding MNTA

RA Capital Management's MNTA Position: Q3 2020 in Review

RA Capital Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 2,531,445 shares — an estimated $84.2M sold.

RA Capital Management first reported a position in MNTA in Q2 2018 and held it in 7 quarters. The position peaked at $84.2M in Q2 2020. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

  • RA Capital Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • RA Capital Management sold 2,531,445 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $84.2M.
  • RA Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2018 and held it in 7 quarters.
  • RA Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $84.2M in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on RA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.